Comparison of clinical outcomes in women with advanced ovarian cancer undergoing neoadjuvant chemotherapy who receive threevs greater than three cycles of chemotherapy after interval cytoreductive surgery

MLA

Jean A. Hurteau, et al. “Comparison of Clinical Outcomes in Women with Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy Who Receive Threevs Greater than Three Cycles of Chemotherapy after Interval Cytoreductive Surgery.” Gynecologic Oncology, vol. 145, June 2017, pp. 71–72. EBSCOhost, https://doi.org/10.1016/j.ygyno.2017.03.169.

APA

Jean A. Hurteau, E.D. Moore, Josephine S. Kim, C. Wang, Tilley Jenkins Vogel, Carolyn V. Kirschner, Gustavo C. Rodriguez, E.N. Prendergast, Joshua G. Cohen, & Rebecca A. Brooks. (2017). Comparison of clinical outcomes in women with advanced ovarian cancer undergoing neoadjuvant chemotherapy who receive threevs greater than three cycles of chemotherapy after interval cytoreductive surgery. Gynecologic Oncology, 145, 71–72. https://doi.org/10.1016/j.ygyno.2017.03.169

Chicago

Jean A. Hurteau, E.D. Moore, Josephine S. Kim, C. Wang, Tilley Jenkins Vogel, Carolyn V. Kirschner, Gustavo C. Rodriguez, E.N. Prendergast, Joshua G. Cohen, and Rebecca A. Brooks. 2017. “Comparison of Clinical Outcomes in Women with Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy Who Receive Threevs Greater than Three Cycles of Chemotherapy after Interval Cytoreductive Surgery.” Gynecologic Oncology 145 (June): 71–72. doi:10.1016/j.ygyno.2017.03.169.